Targeting the Gut-brain Axis to Facilitate Weight Loss in High Fat Diet Consumers

Yale University

Status and phase: Terminated; Phase 4

Conditions: Overweight and Obesity

Treatments: Dietary Supplement: RiduZone (90% OEA); Drug: Placebo

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT04614233

1R01DK126295-01A1 (U.S. NIH Grant/Contract)

2000028769

Details and patient eligibility

About

The primary objective is to test if fat intake moderates the ability of oleoylethanolamide (OEA) to improve weight loss maintenance after the LEARN® weight loss program.

Full description

The proposed work takes a precision medicine approach to obesity treatment and focuses specifically on weight loss maintenance. We propose to optimize a stratification strategy, using neural, metabolic and behavioral measures to identify individuals who will maintain clinically significant weight loss by daily supplementation with the fatty acid amide, oleoylethanolamide (OEA) following a gold-standard behavioral weight loss program. We will also test a model underlying the efficacy of our intervention to provide insight for the further development of therapeutic avenues. Our first aim is to conduct a randomized double-blind placebo-controlled trial to determine if fat intake moderates the ability of OEA to improve weight loss maintenance after the (LEARN®) weight loss program. We predict fat intake will strongly moderate the ability of OEA to produce clinically significant weight loss and weight loss maintenance 4- and 12-months) after LEARN and that this should not be influenced by sex.

Our second aim is to test if the Dietary Fat and Sugar intake questionnaire (DFS) is associated with measures of saturated fat intake and to optimize a clinically useful stratification strategy. Towards this end we will: (1) perform a neuroimaging study to assess brain response to a high fat milkshake (2) assess blood-based biomarkers of fat intake and synthesis; and (3) collect dietary intake records and food frequency questionnaires (FFQs). We predict that (1) the DFS predicts measures of saturated fat intake (2) that baseline dorsal striatal (DS) response to milkshake predicts weight loss in the OEA but not the placebo group and that connectome based predictive modeling (CPM) reveals a "neural fingerprint" that predicts weight loss on OEA; and (3) LASSO regression will identify baseline measures that best predict outcome to inform selection of a practical clinical stratification recommendation.

Our third aim is to test a model of OEA effectiveness. We predict that weight loss outcome is associated with shifts in fat preference and intake and these effects are mediated by increases in DS response to milkshake in the OEA but not placebo group. We will also test whether high fat diet (HFD) is associated with performance on reinforcement and cognitive measures or changes in energy expenditure or substrate utilization. If so, we will test whether these associations and their reversal by OEA contribute to outcome mediation.

Enrollment: 64 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Ages 18-55
• Right-handed with a score of ≥ +50 on the modified Edinburgh handedness scale
• English-speaking
• BMI > 25.0
• Comfortable with the fMRI procedures during the mock scanning session and rate milkshake as at least mildly liked

Exclusion criteria

• Serious or unstable medical illness (e.g., cancer)
• Past or current history of alcoholism or consistent drug use
• Current major psychiatric illness as defined by DSM-IV criteria including eating disorders
• Medications that affect alertness (e.g., barbiturates, benzodiazepines, chloral hydrate, haloperidol, lithium, carbamazepine, phenytoin, etc.)
• History of major head trauma with loss of consciousness
• Ongoing pregnancy
• History of metalworking, injury with shrapnel or metal slivers, or major surgery
• History of pacemaker or neurostimulator implantation
• Known taste or smell dysfunction
• A diagnosis of diabetes
• Any known allergy to foods used in the study, or any known life-threatening food allergy
• Tobacco use

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

64 participants in 2 patient groups, including a placebo group

RiduZone (90% Oleoylethanolamide (OEA))

Experimental group

Description:

Participants will be randomly assigned to take 2 capsules of RiduZone (each capsule contains 90% OEA) daily for 16 months.

Treatment:

Dietary Supplement: RiduZone (90% OEA)

Placebo

Placebo Comparator group

Description:

Participants will be randomly assigned to take 2 capsules of placebo daily for 16 months.

Treatment:

Drug: Placebo